According to recent data erythropoietin receptor (EPOR) is expressed not only by bone marrow erythroid progenitors but by endothelial- and cancer cells and it was suggested that erythropoietin (EPO) may affect their functions as well. We have analyzed the effects of recombinant human erythropoietin-a ?(rHuEPOa) on radiation sensitivity of EPOR+ human epidermoid carcinoma (A431) xenograft model. In vivo rHuEPOa treatment was started after tumor cell inoculation into SCID mice. 5 Gy irradiation was performed on day 14, the effect of which was measured on day 22. Hemoglobin level, tumor-associated microvessels and HIF-1α expression of the xenograft were monitored during the experiment. rHuEPOa administration prevented the development of tumorinduced anemia of SCID mice and reduced the level of HIF-1α expression of the xenograft tumor without affecting tumor growth. We have found that rHuEPOa treatment significantly increased the efficacy of antitumor effect of irradiation which was partly mediated by complex effects on tumorassociated microvessels. In vitro rHuEPOa did not affect proliferation of A431 cells but enhanced the antiproliferative and proapoptotic effects of irradiation. We concluded that rHuEPOa administration positively modulated the antitumoral effects of irradiation at least by two pathways, decreasing systemic hypoxia resulting in decreased tumoral HIF-1α expression and enhancing direct effects on tumor-associated microvessels.
|Translated title of the contribution||Human recombinant erythropoietin-a increases the efficacy of irradiation in preclinical model|
|Number of pages||9|
|Publication status||Published - Dec 1 2007|
ASJC Scopus subject areas